An open clinical trial of venlafaxine treatment of fibromyalgia

Psychosomatics
M M DwightP E Keck

Abstract

Of 15 patients with fibromyalgia who were first evaluated for the presence of Axis I psychiatric diagnoses by use of the Structured Clinical Interview for DSM-IV, 11 completed an open 8-week trial with the novel antidepressant venlafaxine. Six (55%) of 11 completers experienced a > or = 50% reduction of fibromyalgia symptoms. The presence of lifetime psychiatric disorders, particularly depressive and anxiety disorders, predicted a positive response to venlafaxine. These findings suggest that it is important to assess for comorbid psychiatric disorders in patients with fibromyalgia and that venlafaxine may be helpful to some of these patients.

References

Apr 11, 1992·The American Journal of Medicine·J I HudsonL Schlesinger
Jan 11, 1991·International Journal of Psychiatry in Medicine·H G Pope, J I Hudson
Mar 1, 1990·Arthritis and Rheumatism·D L GoldenbergA L Komaroff
Jan 1, 1995·Arthritis and Rheumatism·F WolfeL Hebert
Jan 1, 1959·The British Journal of Medical Psychology·M HAMILTON
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON

❮ Previous
Next ❯

Citations

May 7, 2008·Der Schmerz·C SommerD O Nutzinger
Sep 15, 2005·Current Pain and Headache Reports·Kathryn Baker, Andre Barkhuizen
May 30, 2003·Current Psychiatry Reports·Ashwin A PatkarPrakash S Masand
Jun 1, 2006·Current Psychiatry Reports·Lesley M Arnold
Aug 5, 2005·Current Treatment Options in Neurology·Raphael J Leo
Jun 28, 2005·Annales de réadaptation et de médecine physique : revue scientifique de la Société française de rééducation fonctionnelle de réadaptation et de médecine physique·M A González-ViejoM I Hernández-Morcuende
May 3, 2003·Neuroscience Letters·Fabien MarchandAlain Eschalier
Aug 10, 2001·Journal of Pain and Symptom Management·R S KiserP N Fuchs
Jul 10, 2003·Best Practice & Research. Clinical Rheumatology·Srinivas G Rao, Robert M Bennett
Jun 2, 2000·European Journal of Pain : EJP·U M AnderbergL von Knorring
Mar 13, 2002·European Journal of Pain : EJP·Tiina TasmuthEija Kalso
Sep 16, 2008·Journal of Women's Health·Christine N HuynhLaura A Morgan
May 13, 1999·Current Opinion in Rheumatology·D Buskila
May 21, 2003·American Journal of Therapeutics·Bill McCarbergSteven M Schmidt
Apr 6, 2000·Psychosomatics·L M ArnoldJ A Welge
Nov 22, 2002·Psychosomatics·Anita H Clayton, Juliana Kaltsounis-Puckett
Jun 10, 2006·Arthritis Research & Therapy·Lesley M Arnold
Feb 8, 2006·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Hülya Gültekin, Vefadar Ahmedov
Dec 1, 2006·Neuropsychiatric Disease and Treatment·Chantal Moret, Mike Briley
Nov 14, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Mei-Chun Hsiao
Nov 1, 2011·Pain Management·Deven Karvelas, Sridhar V Vasudevan
Nov 1, 2005·Women's Health·Andrew J Holman
Jul 15, 2004·Current Rheumatology Reports·Leslie J Crofford
May 1, 2008·Rheumatology·S PerrotUNKNOWN CEDR (Cercle d'Etude de la Douleur en Rhumatologie France), French Rheumatological Society, Pain Study Section
Mar 20, 2013·Expert Opinion on Pharmacotherapy·Cheryl D BernsteinDawn A Marcus
May 26, 2006·Expert Opinion on Pharmacotherapy·Rebecca L Robinson, Megan L Jones
Jan 1, 2006·International Journal of Psychiatry in Clinical Practice·Pedro L Delgado
Oct 22, 2002·Expert Opinion on Investigational Drugs·Kim Lawson
Sep 8, 2009·Expert Opinion on Investigational Drugs·Srinivas G Rao
Jul 9, 2008·Current Medical Research and Opinion·Chi-Un PaeBoudewijn Van Houdenhove
Feb 20, 2016·Pain Practice : the Official Journal of World Institute of Pain·Eiad A Ramzy
Oct 17, 2007·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Lesley M Arnold
May 14, 2011·Psychosomatics·Marina Díaz-MarsáJosé Luis Carrasco
Sep 1, 2010·Asian Journal of Psychiatry·Kaustav ChakrabortySuresh Kumar
Apr 14, 2010·The Psychiatric Clinics of North America·Lesley M Arnold
Jul 22, 2008·Rheumatic Diseases Clinics of North America·Serge PerrotFrançoise Laroche
Nov 3, 2007·Seminars in Arthritis and Rheumatism·Piercarlo Sarzi-PuttiniFabiola Atzeni
Nov 3, 2007·La Revue de médecine interne·L AuquierS Perrot
May 1, 2007·Annales de réadaptation et de médecine physique : revue scientifique de la Société française de rééducation fonctionnelle de réadaptation et de médecine physique·D MaquetJ-M Crielaard
Oct 17, 2006·Musculoskeletal Care·Howard A Bird
May 28, 2004·Pharmacotherapy·Dale R GrotheDominick Albano
Feb 12, 2004·Arthritis and Rheumatism·Jeanne K TofferiPatrick G O'Malley

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.